Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
ARQTArcutis Biotherapeutics(ARQT) Newsfilter·2024-02-29 05:00

Arcutis to receive a 25millionupfrontpayment,andiseligibletoreceivepotentialdevelopmentandcommercialmilestonepayments(totaling25 million upfront payment, and is eligible to receive potential development and commercial milestone payments (totaling 40 million), as well as tiered, double-digit royalties Agreement offers pathway to potentially offering a novel non-steroidal topical option to the millions of Japanese patients suffering from inflammatory skin diseases WESTLAKE VILLAGE, Calif. and TOKYO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceuti ...